Scottish Medicines Consortium accepts Revestive® ▼ (teduglutide) for use in NHS Scotland for adult patients with short bowel syndrome

London, UK – Feb 10, 2020, Takeda is pleased to announce that the Scottish Medicines Consortium has accepted Revestive (teduglutide) for use in adult patients with short bowel syndrome (SBS), after previously issuing advice restricting its use to paediatric patients only (aged 1-17 years) 2018i. Teduglutide is the only licensed medicine for the treatment of Short Bowel Syndrome (SBS). The acceptance is in the context of an approved NHS Scotland Patient Access Scheme agreement between NHS Scotland and Takeda.    SBS is a chronic, rare condition. Patients affected by SBS are varied depending on the extent and location of intestinal loss. SBS is characterised by an inability to maintain protein-energy fluid, electrolyte or micronutrient balances when on a normal diet.ii  SBS patients with intestinal failure need parenteral (intravenous) support (nutrition and/or fluids) through a catheter that lasts 10-12 hours over 3-7 days of the week, which can cause complications, such as serious catheter infections. Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue designed to improve the absorption of nutrients and fluid from the remaining gastrointestinal tract and enhances key structural and functional adaptions in the intestinal mucosaiii.    Commenting on the acceptance, Jon Neal, Managing Director Takeda UK & Ireland, commented: ‘We are delighted that the Scottish Medicines Consortium has recognised the benefits of treatment with teduglutide for patients with Short Bowel Syndrome with type III intestinal failure. SBS has the potential to be a lifelimiting condition, associated with reduced quality of life for patients and the threat of complications associated with parenteral support. With no alternative medicines licensed for the treatment of SBS, we are pleased that we have been able to work collaboratively with the SMC to make teduglutide available for patients in need.’ 

Carolyn Wheatley from the patient group PINNT (Support and advocacy group for people on home artificial nutrition), also commented, ‘We recognise that home parenteral nutrition is a life-saving treatment however, it can be a burden as well as a blessing. Rigourous procedures to follow, impaired sleep, disruption to normal life as well as difficult decisions to be made about employment and life-style choices. Any relief from nightly infusions would relieve the burden on both the patient and carers; improved sleep with an opportunity for an improvement in quality of life and possibly returning to work. We are delighted that the SMC has recognised the high level of unmet needs amongst patients with short bowel syndrome and have accepted teduglutide to meet this need.’ 

About Revestive Revestive contains the active substance teduglutide, a glucagon-like peptide-2 (GLP-2) analogue.iii  In the UK, it is indicated for the treatment of patients aged one year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. iii  Revestive received Market Authorisation in Europe in 2012 for the treatment of adult patients with SBS, who should be stable following a period of intestinal adaptation after surgery.  

About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modalitydiverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com/en-gb.